

Monthly DRUP Study Newsletter #77, 01 September 2022

The Drug Rediscovery Protocol (DRUP Trial):

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

3rd of September 653 participants will be climbing Passo dello Stelvio in this year's edition of

- Stelvio For Life -

We wish them the best of luck!



Highlight:

Nivolumab immunotherapy now available for all cancer patients with a MSI tumor profile

Study update

To date, a total of 2149 patients have been submitted to the stage 1 and 2 DRUP cohorts and more than 50% (1102) of these have started a study treatment.

News

We are very proud to announce that the immunotherapy nivolumab is now accessible to all cancer patients with a metastatic MSI-H cancer. The Dutch healthcare institute (ZINL) has reviewed the complete, uncensored data from the stage 3 tumor agnostic cohort of MSI-H patients treated with nivolumab within DRUP and concluded that the data fulfilled all criteria for introduction into the Dutch Health Care system and provided a very significant extension of life expectancy in this vulnerable patient population. This MSI profile occurs in 1-2% of all metastatic cancer patients and the results show that >40% of these patients, who no longer had other treatment options, have long-term benefit from this. This is a great achievement. **Thanks to everyone who has made this possible!**

For more info see the (Dutch) press release on the NKI website: [Immuuntherapie vergoed voor kankerpatiënten met zeldzaam tumorprofiel die geen andere behandelopties meer hebben | AVL](#)

Study amendment

In July **the 16th protocol amendment** was submitted to the Ethics Committee. Among other things this amendment included the addition of tepotinib as new study drug. In the meanwhile this amendment has been approved and we hope to be able to add this new treatment to the study very soon. We will keep you posted on the progress.

Event & meetings

Stelvio For Life edition 2022 is almost about to take place - the 3rd of September 653 participants will be climbing Passo dello Stelvio to support personalized cancer treatment and the DRUP study. A record yield of €1.089.981 has already been donated with for the first time participation of the maximum number of people. Thank you all in advance!

The ESMO Annual World congress is being held September 9th – 13th. In this context we are very excited to inform you that the DRUP study will be well presented with two accepted abstracts; *'Limited effect of pembrolizumab in patients with breast cancer patients harbouring high mutational load 140-290 - results from the Drug Rediscovery Protocol (DRUP)'* and *'Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: results of a tumor-agnostic DRUP trial cohort'*.

Warm regards,

Principal Investigators: Henk Verheul, Hans Gelderblom, Emile Voest
Study Coordinators: Laurien Zeverijn, Gijs de Wit, Birgit Geurts, Ilse Spiekman
Clinical Project Manager: Lena Bilet

Table 1: List of pharmaceutical companies & study drugs

Confidential, list might be subjected to change

Currently available

<u>Amgen</u> Panitumumab	<u>Eisai</u> Lenvatinib	<u>Bayer</u> Regorafenib	<u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab
<u>BMS</u> Nivolumab Ipilimumab	<u>AstraZeneca</u> Olaparib Durvalumab	<u>Clovis Oncology</u> Rucaparib	Vemurafenib+ Cobimetinib Vismodegib
<u>Novartis</u> Dabrafenib Nilotinib Trametinib Ribociclib Alpelisib	<u>Pfizer</u> Axitinib Crizotinib Sunitinib Palbociclib Talazoparib, dacomitinib Lorlatinib	<u>MSD</u> Pembrolizumab	Atezolizumab+ bevacizumab Alectinib Entrectinib
	<u>Lilly</u> Abemaciclib	<u>BI</u> Afatinib	<u>Janssen</u> Erdafitinib

Committed

<u>Lilly</u> Selpercatinib	<u>GSK</u> Niraparib	<u>Merck</u> Tepotinib
-------------------------------	-------------------------	---------------------------

Calendar & publicity

September, 3rd Stelvio for Life

September 9th-13th ESMO annual meeting

Table 2: Submission and accrual overview stage 1 & 2 cohorts

Sept 1st, 2022

